A patient is a CYP2D6 ultrarapid metabolizer. Why is this most concerning for a prodrug like codeine?
Choose an answer, then check it.
Clinical Pharmacology · Special Populations
Pharmacogenomics
On this page 6 sections
In 30 seconds
Pharmacogenomics explains why the same dose of a drug can help one person, do nothing for another, and harm a third: inherited variation in metabolizing enzymes, transporters, receptors, and immune genes changes how the body handles or responds to medication. Some variants alter pharmacokinetics — how fast a drug is activated or cleared — while others alter pharmacodynamics or trigger immune reactions independent of dose. A handful of gene-drug pairs already guide real prescribing, and genotype is one input among several, never a replacement for clinical judgment.
The college version
Two Kinds of Genetic Effect
Pharmacogenomic variation falls into two categories. Pharmacokinetic effects involve genes for metabolizing enzymes (especially cytochrome P450 enzymes) or transporters controlling absorption, distribution, and elimination, changing how much active drug reaches its target. Pharmacodynamic and immunologic effects involve genes for receptors, clotting factors, or human leukocyte antigen (HLA) types that change tissue response to a drug already at normal concentration — sometimes causing hypersensitivity unrelated to dose.
The Metabolizer Phenotype Framework
Inherited variants in key enzymes combine into a phenotype along a spectrum: poor metabolizers have little or no activity, intermediate metabolizers have reduced activity, normal metabolizers have expected activity, rapid metabolizers process substrate faster than typical, and ultrarapid metabolizers process it very quickly. The clinical meaning depends on whether the enzyme activates a prodrug or clears an active drug: clearing an active drug means poor metabolizers risk accumulation while ultrarapid metabolizers risk subtherapeutic effect, and activating a prodrug flips the pattern.
Canonical Examples
CYP2D6 shows both directions. Codeine and tramadol are prodrugs CYP2D6 converts to more active opioid metabolites: poor metabolizers get little pain relief, while ultrarapid metabolizers can generate enough active metabolite to cause dangerous sedation or respiratory depression. CYP2D6 also affects tamoxifen, where reduced activation may lessen its anticancer effect.
CYP2C19 activates clopidogrel; loss-of-function alleles reduce the active metabolite and blunt platelet inhibition, a concern after procedures needing reliable clot prevention. It also affects proton pump inhibitors and some antidepressants, altering exposure without a prodrug problem.
CYP2C9 and VKORC1 jointly drive warfarin dose requirements: CYP2C9 affects clearance and VKORC1 affects sensitivity of the clotting-cascade target, explaining much of the variability in stable dosing.
TPMT and NUDT15 affect thiopurine metabolism; reduced activity in either raises risk of severe bone marrow suppression. DPYD affects fluorouracil and capecitabine, where deficient activity risks severe toxicity. UGT1A1 affects irinotecan, where reduced activity raises risk of diarrhea and neutropenia. G6PD deficiency, an X-linked enzyme deficiency rather than a P450 variant, leaves red cells vulnerable to oxidative stress so certain drugs can trigger hemolysis.
HLA associations are immunologic, not metabolic: HLA-B5701 predicts hypersensitivity to abacavir, HLA-B1502 links to severe cutaneous reactions to carbamazepine in certain ancestries, and HLA-B*5801 links to severe hypersensitivity to allopurinol. Testing before exposure identifies who should avoid these drugs entirely.
Practical Realities
Testing can be preemptive, before a triggering drug is prescribed, or reactive, after an unexpected response prompts investigation. Germline genotype does not change over a lifetime, so results are durable and worth documenting in the record for future prescribers. Guideline consortia translate genotype into structured prescribing recommendations that bridge a lab result and a dosing or drug-selection decision.
Direct-to-consumer tests have real limits: they may not test the same variants a clinical lab tests or include all relevant alleles, and generally should not be the sole basis for prescribing without clinical-grade confirmation. Genotype is one input among many — renal and hepatic function, interactions, adherence, and age all still matter, and a favorable genotype does not override poor organ function or a significant interaction. There is also an equity concern: much foundational evidence came from populations that do not reflect global ancestral diversity, so allele frequencies and clinical significance are sometimes less well characterized in underrepresented groups, a gap ongoing research aims to close.
Pharmacogenomics will not replace clinical judgment, but it is steadily becoming one more layer of individualized prescribing alongside age, organ function, and comorbidity.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine everyone's body has a tiny kitchen that breaks down medicine, but not every kitchen has the same equipment. Some kids have a slow oven, some a regular oven, and some a superfast oven that cooks almost instantly. If a medicine needs to be "cooked" (activated) before it works, a kid with the superfast oven gets way more active stuff than intended, while the slow-oven kid barely gets any effect. If the medicine instead needs to be cleared out afterward, the slow-oven kid keeps too much around and the fast-oven kid clears it too quickly to help.
Some kids also have an immune system that reacts to a specific medicine almost like an allergy, no matter how it's cooked or cleared — a totally different kind of difference. Doctors can test which "kitchen" and immune setup a person has, and that result stays true for life, so it gets written down for whenever a doctor picks a medicine for them.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient with reduced TPMT activity is prescribed a thiopurine without prior genetic testing. What clinical risk does this raise, and what testing could have addressed it?
Show answer
Reduced TPMT activity means the thiopurine builds up unmetabolized, raising risk of severe bone marrow suppression; testing TPMT (and NUDT15) beforehand could have flagged this risk.
This is like knowing a kid's oven barely works before handing them something needing quick breakdown — testing first avoids a buildup that can harm the body's blood-cell factory.
Explain why a direct-to-consumer genetic test result should generally not be used alone to make a prescribing decision.
Show answer
A consumer test may not check the same variants a clinical lab checks and may miss clinically important alleles, so it isn't reliable enough alone to guide a prescribing decision without clinical-grade confirmation.
It's like using a toy thermometer instead of a real medical one — it might give an idea, but a doctor needs the accurate reading before deciding.
Quick check
3 questions here. Answers stay hidden until you check.
Which gene pair is most directly tied to variability in stable warfarin dosing?
Choose an answer, then check it.
What distinguishes HLA-associated reactions (abacavir, carbamazepine, allopurinol) from a pharmacokinetic gene effect?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.